로딩 중...
52주 최고가 대비 37.1% 위치
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.
SEC 13F 공시 기준 · 2025-Q1
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2021년 | 2022년 | 2023년 | 2024년 | 2025년 |
|---|---|---|---|---|---|
| 주요 재무실적 (USD) | |||||
| 매출액 | - | $0 | $0 | $25.4M | $53.4M |
| 영업이익 | - | $-226.3M | $-207.8M | $-176.9M | $-55.6M |
| 당기순이익 | - | $-241.3M | $-198.6M | $-169.9M | $-52.5M |
| 잉여현금흐름 (FCF) | - | $-221.7M | $-173.8M | $-170.6M | $-58.3M |
| 수익성 비율 | |||||
| 영업이익률 | - | - | - | -696.8% | -104.0% |
| 순이익률 | - | - | - | -669.4% | -98.2% |
| ROE (자기자본이익률) | - | -67.8% | -111.9% | -251.6% | -21.7% |
| ROA (자산이익률) | - | -63.0% | -86.7% | -131.2% | -19.0% |
| 성장성 비율 | |||||
| 매출 성장률 (YoY) | - | - | - | - | 110.5% |
| EPS 성장률 (YoY) | - | 58.1% | 18.8% | 21.0% | - |
| 투자 지표 & 가치배수 | |||||
| PER (주가수익배수) | - | - | - | - | - |
| PBR (주가순자산배수) | - | 1.9x | 7.9x | 1.6x | 2.1x |
| PSR (주가매출배수) | - | - | - | 4.2x | 9.6x |
| FCF Yield | - | -33.0% | -12.4% | -161.8% | -11.4% |
| 재무 건전성 (안정성) | |||||
| 부채비율 (D/E) | - | 0.01 | 0.01 | 0.02 | 0.01 |
| 유동비율 | - | 15.06 | 4.47 | 1.62 | 7.24 |
MOLINA HEALTHCARE INC
$179.86
$9.4B